Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiffany Teepen

Physician Assistant Las Vegas, NV Physician Assistant

NPI 1720319890 CMS profile 11237241

7195 Advanced Way, Las Vegas, NV 89101

Open in the dashboard

General payments

$1,487

53 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffany Teepen of Las Vegas, NV is reported in the CMS Open Payments database as having received $1,487 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 10
2024 General $168 5
2023 General $26 1
2022 General $412 13
2021 General $646 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Teepen
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tiffany Teepen were reported at $234. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tiffany Teepen Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $646 $132 $37–$438 $132
2022 $412 $155 $48–$522 $149
2023 $26 $167 $52–$557 $160
2024 $168 $178 $55–$600 $164
2025 $234 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Forte Bio-Pharma LLC $574 2 payments
  2. Horizon Therapeutics plc $343 28 payments
  3. DePuy Synthes Sales Inc. $233 8 payments
  4. Goode Surgical Inc $71 4 payments
  5. Ethicon US, LLC $62 2 payments
  6. Pacira Pharmaceuticals Incorporated $52 2 payments
  7. Smith+Nephew, Inc. $51 2 payments
  8. Zimmer Biomet Holdings, Inc. $46 2 payments
  9. Orthofix Medical, Inc. $31 2 payments
  10. Nalu Medical, Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,487 53 payments
Products named General payments · program years 2021–2025
  1. NALOCET Pain $338 1 payment
  2. PROLATE Pain $338 1 payment
  3. PROLATE Pain $235 1 payment
  4. PROLATE Pain $235 1 payment
  5. NALOCET Pain $235 1 payment
  6. PROLATE Pain $235 1 payment
  7. PROLATE Pain $235 1 payment
  8. MONOVISC $204 7 payments
  9. PENNSAID $196 16 payments
  10. DUEXIS $78 7 payments
  11. Other $487 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

166

Median for Physician Assistant: 241

Drug cost

$1,479

Median for Physician Assistant: $4,110

Branded share of claims

63.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 82 $817
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 24 $312
Ibuprofen Generic 34 $271
Tramadol Hcl Generic 15 $46
Meloxicam Generic 11 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$77,823

Of which drugs: $21,981

Medicare patients

206

Average age 73

Services billed

9,725

134 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 25%
Osteoporosis 21%
Depression 19%
Chronic kidney disease 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 40 132 $12,958
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 20 76 $6,995
Injection, methylprednisolone acetate, 1 mg J1010 Office 68 8,520 $848
Injection, methylprednisolone acetate, 80 mg J1040 Office 39 48 $323

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record